Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.
Gecilmara Salviato PileggiGilda Aparecida Aparecida FerreiraAna Paula Monteiro Gomides ReisEdgard Torres Reis-NetoMirhelen Mendes AbreuCleandro Pires AlbuquerqueNafice Costa AraújoAna Beatriz BacchiegaDante Valdetaro BianchiBlanca BicaEloisa Duarte BonfaEduardo Ferreira BorbaDanielle Christinne Soares Egypto BritoÂngela Luzia Branco Pinto DuarteRafaela Cavalheiro Espírito SantoPaula Reale FernandesMariana Peixoto GuimarãesKirla Wagner Poti GomesAdriana Maria KakehasiEvandro Mendes KlumbCristina Costa Duarte LannaClaudia Diniz Lopes MarquesOdirlei André MonticieloLicia Maria Henrique MotaGabriela Araújo MunhozEduardo Santos PaivaHelena Lucia Alves PereiraJosé Roberto ProvenzaSandra Lucia Euzébio RibeiroLaurindo Ferreira Rocha JuniorCamila Santana Justo Cintra SampaioVanderson Souza SampaioEmília Inoue SatoThelma SkareViviane Angelina de SouzaValeria ValimMarcus Vinícius Guimarães LacerdaRicardo Machado XavierMarcelo Medeiros PinheiroPublished in: Advances in rheumatology (London, England) (2021)
Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID-19 to household cohabitants, suggesting a lack of any protective role against SARS-CoV-2 infection. Trial registration Brazilian Registry of Clinical Trials (ReBEC; RBR - 9KTWX6).